GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Amisulpride - BARHEMSYS intravenous injection

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

BARHEMSYS / amisulpride IV

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Single-dose renal PK is not repeated-dose safety

The selected IV PONV studies excluded dialysis; the label does not supply a dialysis protocol.

Before applying: Keep QT and electrolyte precautions visible. Do not transfer oral psychiatric schedules.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

DailyMed / BARHEMSYS exact product label

Product / population
Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.
Renal measure
eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis

Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.

No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.

Renal dosing, restrictions and evidence limits

The official label regards single-dose renal PK changes as not clinically meaningful, including severe impairment without dialysis. It does not establish repeated-dose or dialysis safety. Adult PONV dosing is 5 mg IV for prevention or 10 mg IV for treatment, each infused over 1-2 minutes.

Avoid use with congenital long-QT syndrome or droperidol. ECG monitoring is recommended with conduction disorders, electrolyte abnormalities, heart failure, or other QT-prolonging medicines/conditions. The renal PK finding does not cancel those precautions.

Source revision: 9/2022 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

DailyMed / BARHEMSYS exact product label

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.

Renal method: eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - BARHEMSYS

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.

Renal method: eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Single-dose renal PK is not repeated-dose safety

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

single dose and monitoring

Single-dose renal PK is not repeated-dose safety

The selected IV PONV studies excluded dialysis; the label does not supply a dialysis protocol.

How to use this: Keep QT and electrolyte precautions visible. Do not transfer oral psychiatric schedules.

GlobalRPh RX List - BARHEMSYSDailyMed / BARHEMSYS exact product label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDailyMed / BARHEMSYS exact product labelGlobalRPh RX List - BARHEMSYS
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/barhemsys-drug/

Exact product and population

Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.

RDM56-SCOPE-amisulpride-barhemsys-iv · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

DailyMed / BARHEMSYS exact product label

Open original reference

Open / share this exact local source

DailyMed / Acacia Pharma Ltd · Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.

Renal method: eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Source date: 9/2022
Retrieved: 2026-09-10

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The official label regards single-dose renal PK changes as not clinically meaningful, including severe impairment without dialysis. It does not establish repeated-dose or dialysis safety. Adult PONV dosing is 5 mg IV for prevention or 10 mg IV for treatment, each infused over 1-2 minutes.

Avoid use with congenital long-QT syndrome or droperidol. ECG monitoring is recommended with conduction disorders, electrolyte abnormalities, heart failure, or other QT-prolonging medicines/conditions. The renal PK finding does not cancel those precautions.

RDM56-official-amisulpride-barhemsys-iv-8641c0653a-C1 · Source locator: Sections 2.1, 5.1 and 12.3

Source-specific limits

Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.

No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144
Retrieved
2026-09-10
Exact label title
BARHEMSYS - amisulpride injection, solution
DailyMed Set ID
ab23bc6e-b6a8-165f-e053-2a95a90ab144
Labeler
Acacia Pharma Ltd
DailyMed page updated
2026-06-17
Label revision
9/2022
Renal-function method
eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Source date/version
9/2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7987ba032acc31e291be21ec8dcd9c86bbf003789b398d6aae980d78b5f59ef6
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - BARHEMSYS

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.

Renal method: eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The selected single-dose PK studies found increased exposure with renal impairment but regarded these changes as not clinically meaningful. Severe-renal participants had eGFR below 30 mL/min/1.73 m2 and did not require dialysis. No dialysis regimen is provided.

The labeled adult regimens remain 5 mg IV for prevention or 10 mg IV for treatment, over 1-2 minutes, within the indication's conditions. QT-risk assessment remains necessary; the single-dose renal finding should not be transferred to repeated dosing or oral amisulpride.

RDM56-rxlist-amisulpride-barhemsys-iv-562562b768-C1 · Source locator: Dosage; QT Prolongation; Pharmacokinetics: Patients with Renal Impairment

Source-specific limits

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/barhemsys-drug/
Retrieved
2026-09-10
Renal-function method
eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
00380577b0ca0954c46f52e6f22a409fb35a71fcafd47fa4f6ebe87018c08a29

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/barhemsys-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
bf4f23305e55eb6b0413ce0135a1fcede7883b9fc55365e2a08bec2c07175ec1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report